Insertional mutagenesis has emerged as a major obstacle for gene therapy based on vectors that integrate randomly in the genome. Reducing the genotoxicity of genomic viral integration can, in first approximation, be equated with reducing the risk of oncogene activation, at least in the case of therapeutic payloads that have no known oncogenic potential, such as the globin genes. An attractive solution to the problem of oncogene activation is the inclusion of insulators/enhancer-blockers in the viral vectors. In this study we have used Recombinase-Mediated Cassette Exchange to characterize the effect of integration of globin therapeutic cassettes in the presence or absence of the chicken HS4 and three other putative insulators inserted near Stil, Tal1 and MAP17, three well-known cellular proto-oncogenes in the SCL/Tal1 locus. We show that insertion of a Locus Control Region-driven globin therapeutic globin transgene had a dramatic activating effect on Tal1 and Map17, the two closest genes, a minor effect on Stil, and no effect on Cyp4x1, a non-expressed gene. Of the four element tested, cHS4 was the only one that was able to suppress this transgene-mediated insertional transcriptional activation. cHS4 had a strong suppressive effect on the activation expression of Map17 but has little or no effect on expression of Tal1. The suppressive activity of cHS4 is therefore promoter specific. Importantly, the observed suppressive effect of cHS4 on Map17 activation did not depend on its intercalation between the LCR and the Map 17 promoter. Rather, presence of one or two copies of cHS4 anywhere within the transgene was sufficient to almost completely block the activation of Map17. Therefore, at this complex locus, suppression of transgene-mediated insertional transcriptional activation by cHS4 could not be adequately explained by models that predict that cHS4 can only suppress expression through an enhancer-blocking activity that requires intercalation between an enhancer and a promoter. This has important implications for our theoretical understanding of the possible effects of the insertion of cHS4 on gene therapy vectors. We also show that cHS4 decreased the level of expression of the globin transgene. Therefore, the benefits of partially preventing insertional gene activation are in part negated by the lower expression level of the transgene. A cost/benefit analysis of the utility of incorporation of insulators in gene therapy vectors will require further studies in which the effects of insulators on both the therapeutic gene and the flanking genes are
References
[1]
Pawliuk R, Westerman KA, Fabry ME, Payen E, Tighe R, et al. (2001) Correction of sickle cell disease in transgenic mouse models by gene therapy. Science 294(5550): 2368–2371.
[2]
Imren S, Payen E, Westerman KA, Pawliuk R, Fabry ME, et al. (2002) Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A 99(22): 14380–14385.
[3]
May C, Rivella S, Callegari J, Heller G, Gaensler KM, et al. (2000) Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin 32. Nature 406(6791): 82–86.
[4]
Puthenveetil G, Scholes J, Carbonell D, Qureshi N, Xia P, et al. (2004) Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 104(12): 3445–3453.
[5]
Levasseur DN, Ryan TM, Pawlik KM, Townes TM (2003) Correction of a mouse model of sickle cell disease: Lentiviral/antisickling beta-globin gene transduction of unmobilized, purified hematopoietic stem cells. Blood 102(13): 4312–4319.
[6]
Persons DA, Allay ER, Sawai N, Hargrove PW, Brent TP, et al. (2003) Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 102(2): 506–513.
[7]
Pawliuk R, Bachelot T, Wise RJ, Mathews-Roth MM, Leboulch P (1999) Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 5(7): 768–773.
[8]
Nienhuis AW (2008) Development of gene therapy for blood disorders. Blood 111(9): 4431–4444. 10.1182/blood-2007-11-078121. 11/26/2008.
[9]
Hacein-Bey-Abina S, Garrigue A, Wang GP, Soulier J, Lim A, et al. (2008) Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118(9): 3132–3142. 10.1172/JCI35700. 11/26/2008.
[10]
Hacein-Bey-Abina S, von Kalle C, Schmidt M, McCormack MP, Wulffraat N, et al. (2003) LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 302(5644): 415–419.
[11]
Kohn DB, Sadelain M, Glorioso JC (2003) Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 3(7): 477–488.
[12]
Coffin JM, Hughes SH, Varmus HE (1997) Retroviruses. Plainview, NY: Cold Spring Harbor Laboratory Press. Cold Spring Harbor Laboratory Press p.
[13]
Yusufzai TM, Tagami H, Nakatani Y, Felsenfeld G (2004) CTCF tethers an insulator to subnuclear sites, suggesting shared insulator mechanisms across species. Mol Cell 13(2): 291–298.
[14]
Wallace JA, Felsenfeld G (2007) We gather together: Insulators and genome organization. Curr Opin Genet Dev 17(5): 400–407. 10.1016/j.gde.2007.08.005. 11/26/2008.
[15]
Pikaart MJ, Recillas-Targa F, Felsenfeld G (1998) Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev 12(18): 2852–2862.
[16]
Prioleau MN, Nony P, Simpson M, Felsenfeld G (1999) An insulator element and condensed chromatin region separate the chicken beta-globin locus from an independently regulated erythroid- specific folate receptor gene. EMBO J 18(14): 4035–4048.
[17]
Chung JH, Bell AC, Felsenfeld G (1997) Characterization of the chicken beta-globin insulator. Proceedings of the National Academy of Sciences of the United States of America 94(2): 575–80.
[18]
Chung JH, Whiteley M, Felsenfeld G (1993) A 5′ element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in drosophila. Cell 74(3): 505–14.
[19]
Ramezani A, Hawley TS, Hawley RG (2003) Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 101(12): 4717–4724. 10.1182/blood-2002-09-2991. 11/26/2008.
[20]
Ryu BY, Persons DA, Evans-Galea MV, Gray JT, Nienhuis AW (2007) A chromatin insulator blocks interactions between globin regulatory elements and cellular promoters in erythroid cells. Blood Cells Mol Dis 39(3): 221–228. 10.1016/j.bcmd.2007.05.003. 11/26/2008.
[21]
Malik P, Arumugam PI, Yee JK, Puthenveetil G (2005) Successful correction of the human cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator. Ann N Y Acad Sci 1054: 238–249. 10.1196/annals.1345.030. 11/26/2008.
[22]
Yannaki E, Tubb J, Aker M, Stamatoyannopoulos G, Emery DW (2002) Topological constraints governing the use of the chicken HS4 chromatin insulator in oncoretrovirus vectors. Mol Ther 5(5 Pt 1): 589–598. 10.1006/mthe.2002.0582. 11/26/2008.
[23]
Emery DW, Yannaki E, Tubb J, Nishino T, Li Q, et al. (2002) Development of virus vectors for gene therapy of beta chain hemoglobinopathies: Flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 100(6): 2012–2019. 10.1182/blood-2002-01-0219. 11/26/2008.
[24]
Evans-Galea MV, Wielgosz MM, Hanawa H, Srivastava DK, Nienhuis AW (2007) Suppression of clonal dominance in cultured human lymphoid cells by addition of the cHS4 insulator to a lentiviral vector. Mol Ther 15(4): 801–809. 10.1038/sj.mt.6300103. 11/26/2008.
[25]
Aker M, Tubb J, Groth AC, Bukovsky AA, Bell AC, et al. (2007) Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. Hum Gene Ther 18(4): 333–343. 10.1089/hum.2007.021. 11/26/2008.
[26]
Bouhassira EE, Westerman K, Leboulch P (1997) Transcriptional behavior of LCR enhancer elements integrated at the same chromosomal locus by recombinase-mediated cassette exchange. Blood 90(9): 3332–3344. 10/18/2007.
[27]
Walters MC, Fiering S, Bouhassira EE, Scalzo D, Goeke S, et al. (1999) The chicken beta-globin 5′HS4 boundary element blocks enhancer-mediated suppression of silencing. Mol Cell Biol 19(5): 3714–3726.
[28]
Begley CG, Green AR (1999) The SCL gene: From case report to critical hematopoietic regulator. Blood 93(9): 2760–2770. 11/26/2008.
[29]
Guijarro MV, Leal JF, Fominaya J, Blanco-Aparicio C, Alonso S, et al. (2007) MAP17 overexpression is a common characteristic of carcinomas. Carcinogenesis 28(8): 1646–1652. 10.1093/carcin/bgm083. 11/26/2008.
[30]
Forrester WC, Takegawa S, Papayannopoulou T, Stamatoyannopoulos G (1987) Evidence for a locus activation region: The formation of developmentally stable hypersensitive sites in globin-expressing hybrids. Nucleic Acids Res 15: 10159–10177.
[31]
Forrester WC, Thompson C, Elder JT, Groudine M (1986) A developmentally stable chromatin structure in the human beta- globin gene cluster. Proc Nat Acad Sci (USA) 83: 1359–1363.
[32]
Tuan D, Abeliovich A, Lee-Oldham M, Lee D (1987) Identification of regulatory elements of human beta-like globin genes. Prog Clin Biol Res 251: 211–220.
[33]
Tuan D, Solomon W, Li Q, London IM (1985) The “beta-like-globin” gene domain in human erythroid cells. Proc Nat Acad Sci (USA) 82: 6384–6388.
[34]
Alami R, Greally JM, Tanimoto K, Hwang S, Feng YQ, et al. (2000) Beta-globin YAC transgenes exhibit uniform expression levels but position effect variegation in mice. Hum Mol Genet 9(4): 631–636.
[35]
Kaufman RM, Pham CT, Ley TJ (1999) Transgenic analysis of a 100-kb human beta-globin cluster-containing DNA fragment propagated as a bacterial artificial chromosome. Blood 94(9): 3178–3184.
[36]
Porcu S, Kitamura M, Witkowska E, Zhang Z, Mutero A, et al. (1997) The human beta globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice. Blood 90(11): 4602–9.
[37]
Feng YQ, Lorincz MC, Fiering S, Greally JM, Bouhassira EE (2001) Position effects are influenced by the orientation of a transgene with respect to flanking chromatin. Mol Cell Biol 21(1): 298–309.
[38]
Tanimoto K, Sugiura A, Omori A, Felsenfeld G, Engel JD, et al. (2003) Human beta-globin locus control region HS5 contains CTCF- and developmental stage-dependent enhancer-blocking activity in erythroid cells. Mol Cell Biol 23(24): 8946–8952.
[39]
Wai AW, Gillemans N, Raguz-Bolognesi S, Pruzina S, Zafarana G, et al. (2003) HS5 of the human beta-globin locus control region: A developmental stage-specific border in erythroid cells. EMBO J 22(17): 4489–4500.
[40]
Kim JH, Ebersole T, Kouprina N, Noskov VN, Ohzeki JI, et al. (2008) Human gamma-satellite DNA maintains open chromatin structure and protects a transgene from epigenetic silencing. Submitted.
[41]
Lin CC, Sasi R, Lee C, Fan YS, Court D (1993) Isolation and identification of a novel tandemly repeated DNA sequence in the centromeric region of human chromosome 8. Chromosoma 102(5): 333–339. 10/3/2008.
[42]
Lee C, Critcher R, Zhang JG, Mills W, Farr CJ (2000) Distribution of gamma satellite DNA on the human X and Y chromosomes suggests that it is not required for mitotic centromere function. Chromosoma 109(6): 381–389. 10/3/2008.
[43]
Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ (2001) Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: Effects on in vitro hemopoiesis. Blood 98(10): 3058–3065.
[44]
Delabesse E, Ogilvy S, Chapman MA, Piltz SG, Gottgens B, et al. (2005) Transcriptional regulation of the SCL locus: Identification of an enhancer that targets the primitive erythroid lineage in vivo. Mol Cell Biol 25(12): 5215–5225. 10.1128/MCB.25.12.5215-5225.2005. 11/26/2008.
[45]
Iborra FJ, Pombo A, Jackson DA, Cook PR (1996) Active RNA polymerases are localized within discrete transcription ‘factories’ in human nuclei. J Cell Sci 109: 1427–1436.
[46]
Osborne CS, Chakalova L, Brown KE, Carter D, Horton A, et al. (2004) Active genes dynamically colocalize to shared sites of ongoing transcription. Nat Genet 36(10): 1065–1071.
[47]
Palstra RJ, Tolhuis B, Splinter E, Nijmeijer R, Grosveld F, et al. (2003) The beta-globin nuclear compartment in development and erythroid differentiation. Nat Genet 35(2): 190–194.
[48]
Byrd K, Corces VG (2003) Visualization of chromatin domains created by the gypsy insulator of drosophila. J Cell Biol 162(4): 565–574. 10.1083/jcb.200305013. 4/13/2009.
[49]
Capelson M, Corces VG (2004) Boundary elements and nuclear organization. Biol Cell 96(8): 617–629. 10.1016/j.biolcel.2004.06.004. 4/13/2009.
[50]
Murrell A, Heeson S, Reik W (2004) Interaction between differentially methylated regions partitions the imprinted genes Igf2 and H19 into parent-specific chromatin loops. Nat Genet 36(8): 889–893. 10.1038/ng1402. 4/13/2009.
[51]
Kurukuti S, Tiwari VK, Tavoosidana G, Pugacheva E, Murrell A, et al. (2006) CTCF binding at the H19 imprinting control region mediates maternally inherited higher-order chromatin conformation to restrict enhancer access to Igf2. Proc Natl Acad Sci U S A 103(28): 10684–10689. .
[52]
Hou C, Zhao H, Tanimoto K, Dean A (2008) CTCF-dependent enhancer-blocking by alternative chromatin loop formation. Proc Natl Acad Sci U S A 105(51): 20398–20403. 10.1073/pnas.0808506106. 4/13/2009.
[53]
Wendt KS, Yoshida K, Itoh T, Bando M, Koch B, et al. (2008) Cohesin mediates transcriptional insulation by CCCTC-binding factor. Nature 451(7180): 796–801. 10.1038/nature06634. 4/13/2009.
[54]
Feng YQ, Desprat R, Fu H, Olivier E, Lin CM, et al. (2006) DNA methylation supports intrinsic epigenetic memory in mammalian cells. PLoS Genet 2(4): e65. 10.1371/journal.pgen.0020065. 10/14/2007.
[55]
Feng YQ, Warin R, Li T, Olivier E, Besse A, et al. (2005) The human beta-globin locus control region can silence as well as activate gene expression. Mol Cell Biol 25(10): 3864–3874.
[56]
Fu H, Wang L, Lin CM, Singhania S, Bouhassira EE, et al. (2006) Preventing gene silencing with human replicators. Nat Biotechnol 24(5): 572–576. 10.1038/nbt1202. 10/14/2007.
[57]
Ryu BY, Evans-Galea MV, Gray JT, Bodine DM, Persons DA, et al. (2008) An experimental system for the evaluation of retroviral vector design to diminish the risk for proto-oncogene activation. Blood 111(4): 1866–1875. 10.1182/blood-2007-04-085506. 11/26/2008.
[58]
Walters MC, Fiering S, Bouhassira EE, Scalzo D, Goeke S, et al. (1999) The chicken beta-globin 5′HS4 boundary element blocks enhancer-mediated suppression of silencing. Mol Cell Biol 19(5): 3714–3726. 11/26/2008.
